In CML, mutations in the kinase domain of the BCR::ABL1 fusion gene may induce resistance to tyrosine kinase inhibitors, as was illustrated by case 744, containing multiple such mutations. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.